Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.
Cutaneous & Mucosal Melanoma — 32 Curated Clinical Trials
| NCT Identifier | Title & Sponsor | Phase / Status |
|---|---|---|
| NCT01638676 | A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | PHASE1/PHASE2 RECRUITING |
| NCT02621021 | A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | PHASE2 RECRUITING |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | PHASE1/PHASE2 RECRUITING |
| NCT03567889 | Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | PHASE3 RECRUITING |
| NCT03842943 | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | PHASE2 RECRUITING |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | PHASE1/PHASE2 RECRUITING |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | PHASE1 RECRUITING |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | PHASE2 RECRUITING |
| NCT04594187 | Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma | PHASE2 RECRUITING |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | PHASE1/PHASE2 RECRUITING |
| NCT04844528 | Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers | PHASE2 RECRUITING |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | PHASE1/PHASE2 RECRUITING |
| NCT04899908 | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | PHASE2 RECRUITING |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | PHASE1 RECRUITING |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | PHASE2 RECRUITING |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | PHASE1/PHASE2 RECRUITING |
| NCT05155033 | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | PHASE2 RECRUITING |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | PHASE1/PHASE2 RECRUITING |
| NCT05280314 | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors | PHASE2 RECRUITING |
| NCT05384496 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | PHASE2 RECRUITING |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | PHASE2 RECRUITING |
| NCT05546827 | Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma | PHASE2 RECRUITING |
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | PHASE3 RECRUITING |
| NCT05588453 | Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain | PHASE1/PHASE2 RECRUITING |
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | PHASE1 RECRUITING |
| NCT05655312 | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | PHASE1/PHASE2 RECRUITING |
| NCT05704647 | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | PHASE2 RECRUITING |
| NCT05727904 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | PHASE3 RECRUITING |
| NCT05779423 | Cryoablation+Ipilimumab+Nivolumab in Melanoma | PHASE2 RECRUITING |
| NCT05830058 | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma | PHASE2 RECRUITING |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | PHASE1/PHASE2 RECRUITING |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | PHASE1/PHASE2 RECRUITING |